Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887354 · ClinicalTrials.gov registry record · Phase 4
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 224
- Enrollment target
NCT00887354 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 224 participants.
The verdict
NCT00887354, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 224 participants
- Enrollment target
Study Summary
This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Risedronate
- DRUG Teriparatide
- DIETARY_SUPPLEMENT Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2009-04 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887354
The ClinicalTrials.gov registry entry for NCT00887354 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00887354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887354 about?
NCT00887354 is a clinical study titled "A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture". This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.
What is the current status of trial NCT00887354?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 224 participants. The study started on 2009-04. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00887354?
The interventions under investigation include: Placebo (DRUG), Vitamin D (DIETARY_SUPPLEMENT), Risedronate (DRUG), Teriparatide (DRUG), Calcium (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00887354?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.